Aims/hypothesis The physiological significance of growth factor receptor-bound protein-10 (GRB10) in the pancreas is unclear. We hypothesised that GRB10 is involved in pancreatic apoptosis, as GRB10 binds with a family of cell-survivalrelated proteins implicated in apoptosis. Methods Lentiviral vector small hairpin RNA (shRNA) targeting Grb10 was injected in vivo via an intraductal pancreatic route to target pancreatic tissues in adult mice, which were studied 2 weeks post-injection. Results Using the TUNEL assay, we demonstrated for the first time that in vivo injection of lentivirus shRNA Grb10 directly into the adult mouse pancreas induced apoptosis in both exocrine and endocrine (alpha and beta) cells. This effect was more pronounced in alpha cells. Levels of the pro-apoptotic protein BCL2-interacting mediator of cell death (BIM) in islets was higher in lentivirus shRNA Grb10 than in lentivirus shRNA scramble mice. In the apoptotic pathway, BIM initiates apoptosis signalling, leading to activation of the caspase cascade. We propose that, when complexed with GRB10, BIM is inactive. On activation by stress signalling or, in the present study, following injection of lentivirus shRNA Grb10 into pancreas, BIM becomes unbound from GRB10 and activates the caspase cascade. Indeed, caspase-3 activity in islets was higher in the experimental than in the control group. Apoptosis induced by shRNA Grb10 resulted in a 34% decrease in fasting plasma glucagon. Mice injected with shRNA Grb10 had improved glucose tolerance despite reduced insulin secretion compared with shRNA scramble control mice. Conclusions/interpretation GRB10 is critically involved in alpha cell survival and, as a result, plays an important role in regulating basal glucagon secretion and glucose tolerance in adult mice.
Introduction
Type 2 diabetes mellitus results from an imbalance between insulin secretion and insulin resistance [1] . The insulin resistance involves multiple tissues, including liver and muscle [1, 2] . Overproduction of glucose by the liver, despite the presence of hyperinsulinaemia, is responsible for fasting hyperglycaemia, while impaired muscle glucose uptake primarily accounts for postprandial hyperglycaemia [1, 3, 4] . Type 2 diabetic patients are also characterised by hyperglucagonaemia and enhanced hepatic glucose production in response to glucagon [3, 5] . Progression from normal glucose tolerance to impaired glucose tolerance to type 2 diabetes is characterised by a progressive decline in insulin secretion and plasma insulin concentration [1, [6] [7] [8] [9] [10] and a progressive rise in plasma glucagon concentration [3, 11, 12] .
Beta cell mass is the result of the overall balance between beta cell proliferation (replication and neogenesis) and apoptosis. When the apoptosis rate exceeds the rate of beta cell proliferation, insulin secretion becomes inadequate and hyperglycaemia ensues [13] . While the loss of pancreatic beta cells in type 2 diabetes is well documented [14] , the pathophysiological mechanism(s) responsible for the beta cell loss remain poorly defined. Recent studies have demonstrated that in diabetic individuals [15] alpha cell mass is increased, but the underlying molecular mechanisms responsible for the increase in alpha cell mass remain undefined. To date, no study has examined why alpha cell mass is increased whereas beta cell mass is decreased in the diabetic pancreas.
Early studies focused on the role of growth factor receptorbound protein-10 (GRB10) in the regulation of insulin sensitivity in peripheral tissues, primarily muscle [16, 17] . GRB10 is an adaptor protein that inhibits tyrosine phosphorylation of the insulin/IGF-1/epidermal growth factor (EGF)/growth hormone and other growth factor receptors, thereby impairing downstream signalling pathways [17] . However, most previous GRB10 studies have been conducted in immortalised cell lines in vitro and it is not clear what role GRB10 plays in modulating insulin sensitivity in vivo. Moreover, a recent study using crystallography demonstrated that GRB10 binds to the insulin receptor far too weakly to have any significant physiological effect on insulin action [18] . These results raise questions about the proposed role of the GRB10 protein in the development of skeletal muscle insulin resistance, at least via any effect on insulin receptor phosphorylation [16, 17] . Of note, GRB10 has been shown to be expressed in the rodent and human pancreas [19, 20] . However, no prior study has investigated the role of GRB10 in pancreatic tissues postnatally.
GRB10 has been implicated in apoptotic signalling [21] , and it is highly concentrated in the mitochondria, an organelle involved in the regulation of apoptosis. GRB10 binds with a family of cell-survival-related partners including the IGF-1 receptor, v-raf-1 murine leukaemia viral oncogene homologue 1 (RAF-1), v-akt murine thymoma viral oncogene homologue (AKT) kinases, the p85 subunit of phosphatidylinositol 3-kinase (PI3K), the 14-3-3 adaptor protein and the neuronal precursor cell-expressed developmentally downregulated 4 (NEDD4) ubiquitin ligase [22, 23] . PI3K and AKT play an important role in beta cell survival [24] [25] [26] . Recently, it has been demonstrated that inhibition of the serine threonine kinase, RAF-1, in a beta cell line induces apoptosis in vitro [27] . Interestingly, GRB10 has been shown to participate in RAF-1-mediated cell survival signalling through inactivation of the pro-apoptotic protein B-cell leukaemia/ lymphoma-2 associated agonist of cell death (BAD) in a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-and PI3K/AKT-dependent manner [28] .
Like retroviral vectors, lentivirus vectors do not encode any viral proteins. An advantage of lentivirus vectors is that they do not activate dendritic cells, like adenovirus vectors [29] . Furthermore, they can infect and integrate into both dividing and non-diving cells, they provide high transduction efficiency and sustained gene expression in vivo, they do not induce a significant host immune response [30] [31] [32] and, in contrast to adenovirus vectors, lentivirus vectors can be successfully re-administered [30] . Importantly, our method of viral vector injection in vivo into the adult murine pancreas also permits one to recreate the pathophysiology of a chronic disease that develops in adulthood and avoid the development of compensatory mechanisms that occur when a gene is deleted during embryonic development. This helps to obviate some of the paradoxical findings that have been reported with knockout models, i.e. normal/near-normal muscle insulin sensitivity in mice in which the insulin receptor is knocked out [33] and a homozygous null mutant for GLUT4 (Glut4
) that did not show a diabetic phenotype [34] . Using lentivirus small hairpin RNA (shRNA) silencing experiments, we have provided evidence for a critical role of GRB10 in alpha cell apoptosis. Specifically, we have shown, for the first time, that silencing of Grb10 in the adult mouse pancreas causes alpha cell apoptosis and reduced fasting plasma glucagon levels. To our knowledge, this is the first description of an anti-apoptotic molecule that regulates alpha cell survival in vivo and modulates circulating plasma glucagon levels. Given the important role of GRB10 in apoptotic mechanisms, we postulate that GRB10 is a mediator of apoptosis in the adult pancreas. Our technique, which allows us to deliver lentivirus shRNA specifically into the mouse pancreas in vivo, provides evidence that GRB10 is critically involved in alpha cell survival and, as a result, plays an important role in regulating basal glucagon secretion and glucose tolerance in adult mice.
Methods

Lentivirus construct
We determined that the shRNA sequence 5′-GAACAACGATATTAACTCGTCCGTTCAA GAGACGGACGAGTTAATATCGTTGTTC-3′ against the GRB10 mouse protein was able to effectively inhibit expression of Grb10 (Fig. 1a) in the islets and exocrine tissues (electronic supplementary material [ESM] Fig. 1 ). This shRNA sequence was introduced into a lentiviral vector under the control of the H1 promoter. The polymerase III promoter H1 is active ubiquitously in all cells, because of the housekeeping function of polymerase III. The lentivirus shRNA Grb10 and shRNA scramble were generated by Welgen (Worcester, MA, USA).
Animal studies Male C57BL/6 mice (Charles River, Wilmington, MA, USA) 8 weeks of age were used for all experiments and were maintained on a diet of water and normal chow ad libitum. Animal protocols were approved by the University of Texas Health Science Center Animal Care Committee. Lentiviral shRNA constructs were introduced into the mouse pancreas via the intraductal route, as follows: a 32-gauge catheter (Braintree Scientific, Braintree, MA, USA) was inserted into the cystic duct through a small opening in the gallbladder. The catheter was then advanced into the common bile duct and secured in place with a slipknot of 0/0 suture around the bile duct and catheter to prevent vector reflux into the liver. With a micro clamp placed around the sphincter of Oddi to avoid leakage of the vector into the duodenum, 100 μl lentiviral vector expressing shRNA Grb10 or shRNA scramble at 1×10 8 TU/ml was slowly injected into the pancreatic duct through the catheter. At 1 day postinjection with lentiviral vector, the mice were injected i.p. daily with BrdU (Sigma-Aldrich, St Louis, MO, USA) in PBS at a dose of 50 μg/g body weight for 12 days. At 2 weeks post-lentiviral infection, the entire pancreas was removed for histological examination (see below). Figure 2 shows that, after 48 h, injection of lentivirus coding for the green fluorescent protein (GFP) under the control of promoter cytomegalovirus specifically targeted the pancreatic tissues (ESM Fig. 2 , for lentivirus H1 promoter-shRNA co-expressing GFP). The lentivirus-vector-produced GFP in vivo in the pancreas was not found in any other tissues in the body including heart, lung, liver, brain, leg muscle or kidney by histology or PCR (data not shown).
Intraperitoneal glucose tolerance test and insulin tolerance test Following an overnight fast, mice were weighed and injected i.p. with a bolus of glucose (2 g/kg body weight). Blood glucose levels were determined from tail blood at 0, 10, 15, 30, 60 and 120 min following glucose injection using an Ascensia Breeze 2 glucose meter (Bayer HealthCare, Mishawaka, IN, USA). Plasma insulin concentration was measured at 0, 15, 60 and 120 min on 5 μl (EDTA) samples using the mouse insulin Ultrasensitive ELISA (Alpco Diagnostics, Salem, NH, USA). Fasting plasma glucagon concentration was determined from 50 μl plasma samples (EDTA, aprotinin 500 kIU [Trasylol; Bayer HealthCare, Pittsburgh, PA, USA] for every 1 ml blood) using a mouse glucagon ELISA assay (Alpco Diagnostics). For the insulin tolerance test, following a 5 h fast, mice received an i.p. injection of 0.7 U/kg insulin (Novo Nordisk, Bagsvaerd, Denmark) in PBS.
Immunofluorescent and immunohistochemical analysis Adult mouse pancreatic tissues were fixed by immersion in phosphate buffer with 4% paraformaldehyde and 1% antibodies and control rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The activity of caspase-3 was measured with an antibody (Cell Signaling Technology, Danvers, MA, USA) that detects endogenous levels of the large fragment (17/19 kDa) of activated caspase-3 resulting from cleavage next to Asp175. For proliferation studies, pancreatic tissues were stained with either Ki-67 (M-19) antibody (Santa Cruz) or with rat monoclonal BrdU antibody (Abcam, Cambridge, MA, USA). Antigen retrieval was performed for Ki-67 and BrdU antibodies by boiling sections for 10 min in 10 mmol/ l citrate buffer followed by cooling for 30 min to room temperature. Nuclei were counterstained with DAPI (Vector Laboratories, Burlingame, CA, USA). The fluorescent secondary antibodies used included donkey anti-goat-fluorescein, goat anti-mouse-fluorescein, goat anti-rabbit Texas Red and donkey anti-goat Texas Red (Santa Cruz). The beta cell area represents the surface area of cells staining positively for insulin immunostaining divided by the total pancreatic surface scanned with an Olympus FV-1000 laser scanning confocal microscope. The insulin-positive and total pancreatic areas were quantified with Image J (National Institutes of Health, Bethesda, MD, USA). Beta cell mass was calculated as beta cell area multiplied by pancreatic wet weight. At least three mice were analysed per condition. TUNEL assay was measured with the in situ Cell Death Detection Kit, TMR Red (Roche Diagnostics, Indianapolis, IN, USA). Quantification of pancreatic transduction by lentiviral GFP vector following intraductal injection was obtained by visualising the GFP expression area of the pancreas performed in four sections per animal, separated by 200 μm. To quantify the percentage of the area expressing GFP, images were analysed with ImageJ software to determine the GFP-positive area of each image. Briefly, images were subjected to thresholding using a GFP-negative control section from untreated pancreatic tissue as a reference for background GFP level. The percentage of area with brightness values equal to or exceeding the threshold value within each image was then calculated and averaged for all four images per animal. Pancreatic tissue was stained with haematoxylin and eosin to look for evidence of inflammation (pancreatitis) at day 2 and day 14 post-injection of the lentivirus.
RNA extraction and real-time PCR For comparison, we examined the expression of GRB10 in human skeletal muscle, adipose tissue and pancreas. Total RNA was extracted from approximately 20-30 mg of frozen skeletal muscle and fat tissue using TRIzol reagent (Invitrogen, Carlsbad, CA, USA).
Human pancreatic RNA was obtained from Clontech (cat. #636577). The integrity of each RNA sample was confirmed post-extraction using denaturing (glyoxal) agarose gel electrophoresis. Reverse transcription was carried out with 0.5 μg total RNA using the ImProm II reverse transcription system (Promega, Madison, WI, USA) according to the manufacturer's instructions. Real-time quantitative PCR was then performed using 2 μl cDNA with a primer and 5′-terminal 6-carboxyfluorescein (FAM)-labelled TaqMan probe mix from Applied Biosystems (assay ID Hs00193409; Foster City, CA, USA). Relative expression values were calculated from a standard curve, which consisted of a twofold dilution series from a pooled sample of each cDNA, and they were normalised to 18S ribosomal RNA. Data for PEPCK (also known as PCK1) were normalised to GAPDH mRNA levels, which were not affected by shRNA delivery.
Western blot For western blots, equal amounts of total protein were separated on a 10% and 15% SDS/PAGE and transferred onto nitrocellulose membranes. Membranes were then blocked with 5% non-fat milk in 0.1% Tris buffered saline (TBS) Tween-20 and probed with specific antibodies against GRB10 (Santa Cruz), cleaved caspase-3 (Cell Signaling Technology) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; G9545, Sigma-Aldrich). Membranes were then incubated with horseradish peroxidaseconjugated secondary antibody (NA934) and developed with a chemiluminescent reagent (Amersham Bioscience, GE Healthcare, Pittsburgh, PA, USA).
Statistical analysis
Results are presented as mean ± SEM. Statistical comparisons were performed with Student's unpaired t test or one-way ANOVA, as appropriate. Results were considered to be statistically significant when p<0.05.
Results
GRB10 localisation in the pancreas
To determine the localisation of GRB10 in the adult mouse pancreas, we performed confocal laser microscope studies. Co-staining of pancreatic sections of C57BL/6 mice with a monoclonal anti-insulin antibody and a polyclonal anti-GRB10 antibody revealed that GRB10 protein is present in the pancreatic endocrine and exocrine tissues (Fig. 3) . Overlay of the GRB10 with other antibody-staining images revealed co-localization of GRB10 in endocrine (alpha, beta and delta) and exocrine (amylase and ductal cells) cells (Fig. 3) . By quantitative RT-PCR, we demonstrated that GRB10 also is expressed in human pancreas. Of the tissues examined, GRB10 mRNA levels were highest in the human pancreas, being almost twice as abundant as in human skeletal muscle (ESM Fig. 3 ).
Lentiviral vector injection into the mouse pancreas
We developed a technique that allows injection of the viral vector in vivo directly into the pancreas in adult mice (see 'Animal studies' under experimental procedures) and demonstrated that, 48 h post-injection, the lentivirus vector produced GFP in vivo in the pancreas ( Fig. 2 ; see also ESM Fig. 2) and not in any other tissues in the body. Quantitative morphometric analysis of pancreatic transduction by the lentivirus vector, based on GFP production, showed that 60% of the tissue produced GFP. Importantly, expression was detected in the pancreas even after 14 days. Lentiviral-vectorconstructed shRNA targeting Grb10 was injected in vivo via the intraductal pancreatic route to target the pancreatic tissues in 8-week-old adult mice (n06), which were studied 2 weeks post-injection. Control mice (n05) were injected with a lentivirus shRNA scramble using the same technique. BrdU, a marker of cell proliferation, was administered daily for 2 weeks by i.p. injection to both experimental and control groups. Following the lentiviral vector injection, activity, food intake (daily food intake in g over the 14 days post-injection: mice shRNA scramble 5.4 ± 0.3; n 05 vs mice shRNA Grb10 5.9±0.5; n06) and weight gain were similar in the shRNA Grb10 and shRNA scramble groups (ESM Fig. 4) . No diarrhoea was observed in the control and experimental groups after the lentivirus injection.
In the experimental group injected with lentivirus shRNA Grb10, histological examination demonstrated the suppression of GRB10 protein production using western blot (Fig. 1b) . In the experimental group injected with shRNA Grb10, we did not observe any increase in cell proliferation with antibodies against BrdU or Ki-67 (data not shown). In contrast, using the TUNEL assay, we demonstrated for the first time that in vivo injection of lentivirus shRNA Grb10 directly into the adult mouse pancreas induced apoptosis in both exocrine and endocrine tissues (Fig. 4a-c) . The major apoptotic physiological effect of shRNA Grb10 in the adult pancreas was observed against the alpha cells ( Fig. 4d; ESM  Fig. 5 ) and was associated with a 34% decrease in fasting plasma glucagon concentration (86±12 vs 129±7 ng/l, p< 0.05). However, as pointed out previously [35] , the in vivo histological TUNEL assay for apoptosis of pancreatic beta cells is limited by the small number of these cells that are undergoing apoptosis at any given time. Similarly, it is technically difficult to accurately quantify in vivo the number of glucagon cells that are undergoing apoptosis. Another obstacle that complicates the quantification of apoptosis in vivo is the speed at which cells die and disappear. The time from initiation of apoptosis to its completion can be as short as 2-3 h [36] . Another challenge in quantifying apoptosis is related to the asynchronous nature of the apoptotic process [37] , and this could explain why the number of beta cells staining for caspase-3 activity exceeds the number of TUNEL-assay-positive beta cells [37] [38] [39] . Nonetheless, our results clearly demonstrate that shRNA Grb10 induced alpha and beta cell apoptosis in vivo within the limits of the methods employed to quantify apoptosis. Interestingly, the level of the pro-apoptotic protein BIM in islets was higher in lentivirus shRNA Grb10 mice compared with lentivirus shRNA scramble mice ( Fig. 5; ESM Figs 6 and 7) . In addition, the caspase-3 activity in islets was higher in the mice injected with lentivirus shRNA Grb10 compared with the control shRNA scramble group (Fig. 5) . Caspase-3 and BIM represent steps that precede the death of cells and would not be expected to modify the structure of the cell. Other investigators have observed the same phenomenon, i.e. an increase in caspase-3 activity without any change in cell architecture [38, 39] . One can also have a situation with increased caspase-3 activity and/or BIM production in which the apoptotic cascade is fully engaged and the cellular architecture is distorted (ESM Figs 6 and 7) . There was no effect of the lentivirus shRNA Grb10 on fasting plasma insulin concentration, which was similar in both groups (492± 658 pmol/l in shRNA Grb10 vs 669±83 pmol/l in shRNA scramble, p0NS). There was no effect of the lentivirus shRNA Grb10 on insulin tolerance test results compared with the lentivirus shRNA scramble group (ESM Fig. 8 ). Mice injected with shRNA Grb10 had improved i.p. glucose tolerance test results (Fig. 6b ) despite reduced insulin secretion (Fig. 6c ) compared with shRNA scramble control mice.
Discussion
It has been demonstrated previously that GRB10 is an antiapoptotic protein in cell lines in vitro [25] . We demonstrate, for the first time in vivo, the important role of GRB10 in the survival of pancreatic cells. The Src-homology 2 (SH2)-and pleckstrin homology (PH)-domain-containing protein, GRB10, has been shown to be produced in the rodent and human pancreas [19, 20] but, to date, no study has delineated the precise distribution of GRB10 expression in the pancreas. We show here that Grb10 is highly expressed in adult mouse pancreatic beta cells (insulin) and at lower levels in alpha cells (glucagon) and delta cells (somatostatin), as well as in the exocrine pancreas (amylase and ductal cells) (Fig. 3) . We have also demonstrated that Grb10 is highly expressed in the human pancreas compared with insulin-sensitive tissues, skeletal muscle and fat (ESM Fig. 3) . We demonstrate that silencing of Grb10 in the adult mouse pancreas causes alpha cell apoptosis and reduced fasting plasma glucagon levels (Figs 4 and 6a; ESM Fig. 5 ). To our knowledge, this is the first description of an anti-apoptotic molecule that regulates alpha cell survival in vivo and modulates circulating plasma glucagon levels.
Recently, overexpression of Grb10 in the HEK293 cell line has been shown to inhibit the activity of BIM, a proapoptotic protein [40] . BIM is regulated at both the transcriptional and post-translational levels [41] . In the present study, the level of the pro-apoptotic protein BIM in islets was higher in mice receiving lentivirus shRNA Grb10 compared with lentivirus shRNA scramble mice (Fig. 5) . In the apoptotic pathway, the protein BIM initiates apoptosis signalling by binding to the B-cell leukaemia/lymphoma 2 (BCL-2)-like pro-survival proteins (BCL-2), BCL2-like protein 1 (BCL-XL), BCL-W, myeloid cell leukaemia 1 (MCL-1) and Bcl gene A1, thereby releasing BAX and/or BAK, which causes a decrease in the mitochondrial outer membrane potential, release of cytochrome c and activation of the caspase cascade [42] . We hypothesise that, when complexed with GRB10, BIM is inactive. Upon cellular activation by stress signalling or, as in the present study, following injection of lentivirus shRNA Grb10 into the pancreas, BIM becomes unbound from GRB10 and causes activation of BAX-BAK, thereby inducing apoptosis by activating the caspase cascade. Indeed, as demonstrated in Fig. 5 , the activity of caspase-3 in islets was higher in the experimental group compared with the control group. The lentivirus shRNA Grb10 also induced exocrine cell apoptosis ( Fig. 4 ; ESM Figs 9 and 10). However, there was no histological evidence of inflammation and pancreatic wet weight, as well as body weight gain, was similar in the two experimental groups (ESM Figs 4 and 11) . Consistent with this, lentivirus has been shown not to induce inflammation, the hallmark of an immune response, at the site of injection [30] .
At day 7 and 14 days post-injection, the amylase level was normal. Therefore, apoptosis of the exocrine tissues in the experimental group injected with the lentivirus shRNA Grb10 did not cause symptoms indicative of chronic pancreatitis. As the exocrine pancreas constitutes more than 95% of total pancreatic tissue [43] , our results indicate that, if only a small percentage of exocrine tissue undergoes apoptosis, the remaining exocrine tissue is capable of compensating for any tissue that is lost.
In mice the majority of cells within the islets are beta cells (approximately 65-75%); glucagon-secreting alpha cells represent less than 20% of the individual islet area [44] . Therefore, one might expect that loss of alpha cells via apoptosis would have a greater physiological impact on glucose homeostasis than the loss of an equivalent or even greater number of beta cells. Indeed, this is precisely what has been observed in partially pancreatectomised patients [45] [46] [47] . Thus, despite a modest decrease in fasting glucagon concentration and a severe reduction in the plasma insulin and C-peptide response to glucose in partially pancreatectomised individuals, glucose tolerance and insulin action are not adversely affected [47] . These results suggest that the decrease in plasma glucagon concentration after subtotal pancreatectomy may be associated with enhanced insulin sensitivity and are consistent with previously published results from our group that demonstrated that a physiological elevation in plasma glucagon concentration in individuals with normal glucose tolerance for as little as 3 days induces moderate to severe insulin resistance [48] . In the present study, injection of lentivirus shRNA Grb10 directly into the pancreas produced a similar phenotype with decreased fasting glucagon concentration (Fig. 6a) and an improved glucose tolerance test despite a decrease in insulin secretion (Fig. 6b) . Thus, simultaneous apoptosis of both alpha and beta cells, induced by lentivirus shRNA Grb10 (Fig. 4) , explains the reduction in fasting plasma glucagon concentration and, consequently, improved i.p. glucose tolerance despite a decrease in insulin secretion.
The reduction in fasting plasma glucagon concentration with maintained fasting plasma insulin level despite the 40% reduction in beta cell mass (ESM Fig. 12 ) was not associated with a decline in fasting plasma glucose concentration. There was no effect of the lentivirus shRNA Grb10 on insulin tolerance test compared with the lentivirus shRNA scramble group (ESM Fig. 8 ). Because, in rodents, hepatic glucose production under fasting conditions is primarily derived from gluconeogenesis [49] and PEPCK is the rate-limiting enzyme for gluconeogenesis, we measured the Pepck mRNA level in the liver. No difference in Pepck mRNA expression was observed in mice injected with shRNA Grb10 or shRNA scramble. The maintenance of normal hepatic Pepck gene expression/activity in mice injected with lentivirus shRNA Grb10 would be expected to maintain gluconeogenesis and basal hepatic glucose production, thus preventing any decline in fasting plasma glucose concentration. Although not measured in the present study, the maintenance of normal circulating catecholamine levels could also prevent the development of hypoglycaemia caused by glucagon deficiency [50] .
In summary, we demonstrate for the first time that lentivirus shRNA Grb10 injected directly into the mouse pancreas induces apoptosis of both endocrine and exocrine cells. These findings represent the first demonstration that GRB10 is an anti-apoptotic protein in vivo. The apoptosis induced by shRNA Grb10 results in a decrease in fasting plasma glucagon concentration and improved i.p. glucose tolerance despite a decrease in glucose-stimulated insulin secretion. Our work provides a novel model to study both the apoptotic and anti-apoptotic signalling mechanisms of GRB10 in the pancreas. We anticipate that this will provide novel insights about the basic cellular/molecular mechanisms that regulate pancreatic beta and alpha cell mass and could have important implications for the pathogenesis of type 2 diabetes, which is characterised by increased glucagon secretion/alpha cell mass and reduced insulin secretion/ beta cell mass [1] .
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